Nexpovio (Selinexor)

Selinexor, the active ingredient in Nexpovio, is a selective inhibitor of nuclear export (SINE) presented as a oral tablet for oral use. It treats relapsed or refractory multiple myeloma and relapsed or refractory diffuse large B‑cell lymphoma in adult patients.

GNH USA supplies Nexpovio as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Nexpovio acts on malignant cells by blocking nuclear export pathways, providing therapeutic options for hematologic cancers. - Relapsed or refractory multiple myeloma: provides an additional option for patients who have progressed after standard therapies. - Relapsed or refractory diffuse large B‑cell lymphoma: offers a treatment alternative for patients whose disease is refractory to conventional regimens. - Investigational solid‑tumor indications: currently evaluated in clinical studies for potential benefit in various solid cancers.

Selinexor may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Nausea: feeling of sickness often accompanied by vomiting. - Anorexia: reduced appetite leading to weight loss. - Thrombocytopenia: lowered platelet count increasing bleeding risk. - Anemia: decreased red blood cells causing weakness. - Vomiting: expulsion of stomach contents.

Serious or Rare Side Effects: - Severe neutropenia: markedly low neutrophil count raising infection risk. - Hepatic toxicity: elevated liver enzymes or liver injury. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Pulmonary embolism: blood clot in the lungs presenting with sudden shortness of breath. - Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.

Before initiating selinexor therapy, clinicians should assess baseline health status and monitor for potential complications. - Monitor blood counts: regular CBC to detect cytopenias. - Assess liver function: periodic LFTs to identify hepatic toxicity. - Avoid in uncontrolled infections: defer treatment until infection is resolved. - Use effective contraception: teratogenic risk unknown, so pregnancy must be avoided. - Review concomitant CYP3A4 inhibitors: may increase drug exposure. - Store at below 25°C: keep in the original pack, protect from moisture.

Selinexor can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may raise selinexor plasma levels and increase toxicity. - QT‑prolonging agents: additive risk of cardiac arrhythmias. - Anticoagulants: heightened bleeding risk due to thrombocytopenia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers: may lower selinexor effectiveness. - Antacids containing aluminum or magnesium: can reduce oral absorption. - Concurrent myelosuppressive chemotherapy: may exacerbate cytopenias.